Pharma BD Deal Intelligence
Lilly agreed to acquire Verve Therapeutics for $10.50/share at closing (~$1.0B equity) plus CVR up to $3.00/share ($300M) tied to VERVE-102 milestones, total up to ~$1.3B. Gains Verve's gene-editing pipeline targeting ASCVD with one-time treatment potential. Completed July 25, 2025. Post-close, on May 25, 2026 Lilly reported positive interim Phase 1b Heart-2 data for VERVE-102: a single dose reduced PCSK9 by up to 88% and LDL-C by up to 62% (1.0 mg/kg cohort), durable to 18 months with no dose-limiting toxicities (n=35); a Phase 2 study is planned to begin enrolling by end of 2026 -- validating the one-time PCSK9 base-editing thesis behind the CVR milestones.